EGFR and non-small cell lung carcinoma: In recent years, the clinical effect of EGFR-TKIs in the treatment of patients with NSCLC has gradually attracted attention, and several clinical trials have proven their effectiveness (Ballard et al., 2016; Wang et al., 2017; Su et al., 2018; Saida et al., 2019; Yomo et al., 2019; Yun et al., 2019; Dai et al., 2020).